SEATTLE, March 1,
2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq:
CTIC), a commercial biopharmaceutical company focused on the
development and commercialization of novel targeted therapies for
blood-related cancers, today announced that the management team
will present a corporate overview at the 43rd Annual
Cowen Health Care Conference on Wednesday,
March 8, 2023 at 10:30 a.m. ET
(7:30 a.m. PT).
A link to the live and archived webcast may be accessed on the
CTI BioPharma website under the Investors & Media section:
Events and Presentations.
About CTI BioPharma Corp.
CTI BioPharma is a commercial biopharmaceutical company focused
on the development and commercialization of novel targeted
therapies for blood-related cancers that offer a unique benefit to
patients and their healthcare providers. CTI has one FDA-approved
product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor,
that spares JAK1. VONJO is approved for the treatment of adults
with intermediate- or high-risk primary or secondary
(post-polycythemia vera or post-essential thrombocythemia)
myelofibrosis with a platelet count below 50 × 109/L. This
indication is approved under FDA accelerated approval based on
spleen volume reduction. Continued approval for this indication may
be contingent upon verification and description of clinical benefit
in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA
study of VONJO in patients with myelofibrosis and severe
thrombocytopenia as a post-marketing requirement. For more
information, please visit www.ctibiopharma.com.
VONJO® is a registered trademark of CTI BioPharma Corp.
Investor Relations and Media Contacts:
Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-43rd-annual-cowen-health-care-conference-301760024.html
SOURCE CTI BioPharma Corp.